A qualified oral film project reaches released pilot product in about 6–10 weeks: feasibility 3–5 business days, formula development 2–4 weeks, sample iteration 1–3 weeks, pilot production 2–4 weeks, then roughly a week for third-party testing and the Lot Release Packet. Those are development targets. Packaging lead time and unanswered questions are what push a project past ten weeks.
| Phase | Published duration | Can overlap with | What ends the phase |
|---|---|---|---|
| Feasibility review | 3–5 business days | Nothing; it needs the complete brief first | A written yes, no, or redesign on dose, strip size, serving, flavor and package |
| Formula development | 2–4 weeks | Packaging dielines, artwork drafting, ingredient documentation | First samples that meet the written sensory and handling criteria |
| Sample iteration | 1–3 weeks | Artwork proofing, test-method selection, sachet and carton ordering | Signed sample approval |
| Pilot production (500 boxes) | 2–4 weeks | Nothing after components arrive; they must be on site before it starts | About 10,000 strips (20-count) or 15,000 strips (30-count) converted, sealed and packed |
| Testing and release | About 1 week | Reorder planning | Third-party results through ILS Lab and the Lot Release Packet for the lot |
| Total to released pilot product | 6–10 weeks | Product you can ship |
Six to ten weeks, if nobody stalls
Our published path from complete brief to released pilot product is 6–10 weeks. It assumes ingredient documents arrive with the brief, one person approves samples, and packaging starts the week feasibility clears. Lose any of those and lab time stays flat while calendar time grows. In the table, formulation and packaging overlap; pilot production and packaging cannot.
Feasibility: 3–5 business days
The review checks the request against our development targets: a 22 × 32 mm strip, roughly 100–300 mg finished, up to about 250 mg of one active, a 30–60 second dissolve. Anything beyond that is redesigned (two strips, a lower amount, another ingredient form) before the clock starts. Drug-pathway actives end the review.
Development, iteration and packaging: 3–7 weeks
Formula development runs 2–4 weeks, sample iteration 1–3. Each round costs about a week: cast, dry, cut, ship, taste, respond. Two rounds is normal; a third means the pass/fail criteria were never written down.
Packaging runs in parallel. Dielines start when feasibility clears; artwork freezes at sample approval; printed sachets and cartons must be on site before pilot week one, or the pilot waits.
Release is one clock; shelf life is another
Release takes about a week: third-party testing through ILS Lab, then the Lot Release Packet. Shelf life is a separate study. FDA does not require an expiration date on a supplement, but AHPA's guidance summarizes the agency's position that a printed date must be supported by data. The pharmaceutical reference, ICH Q1A(R2), is 6 months at 40 °C/75% RH accelerated and at least 12 months at 25 °C/60% RH long-term, tested every 3 months in year one. Our 24-month target follows that logic: launch on accelerated data with the real-time study running, and never print a date with no study underway.
Worked example: a 100 mg single-active strip in 20-count boxes
Day 0, complete brief. Day 5, feasibility clears and dielines start. Weeks 1–3, formulation, artwork drafted alongside. Week 4, one iteration round, artwork proofed. Week 5, components delivered. Weeks 6–8, pilot production of 500 boxes. Week 9, testing and release. Nine weeks.
Now add a second iteration round (one week) and release artwork after sample approval instead of proofing it alongside (about two weeks of print and delivery the pilot cannot start without). Same product, week twelve.
Set the reorder date at pilot approval
Before the pilot ships, record raw-material lead times, leftover packaging, testing windows and the sales rate that triggers a reorder, then pick the decision date. A reorder repeats pilot production and release even when formulation is done.
Common questions
Not by promise, only by preparation. The controllable items are a complete brief with ingredient documents, one approver with written criteria, and packaging components ordered during formulation. Everything else is lab and print time.
No. Release testing answers whether the lot meets its specification. Shelf life is a separate accelerated and real-time study that runs after release and should be underway before a dated label prints.
Open decisions, late artwork, and missing ingredient documentation, in that order. None of them are manufacturing time.
Primary sources
- FDA — Q1A(R2) Stability Testing of New Drug Substances and Products
- AHPA — Guidance: Shelf Life Dating of Botanical Supplement Ingredients and Products (2011)
- eCFR — 21 CFR Part 111, Current Good Manufacturing Practice for Dietary Supplements
- FDA — Dietary Supplement CGMP Small Entity Compliance Guide
Formula feasibility, packaging, testing, claims, timing, and final quantities depend on the exact product. Use this guide to prepare better questions, then confirm the production plan for your project.